Business Context and Reporting Period
This Form 8-K was filed by Harrow Health, Inc. (HROW) on August 6, 2020, reporting an event that occurred on August 1, 2020. The filing details a strategic commercial alliance entered into by the Company's wholly-owned subsidiary, ImprimisRx, LLC.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Agreements
On August 1, 2020, the Company entered into a Commercial Alliance Agreement with Eyepoint Pharmaceuticals, Inc. Key terms include:
- Scope: Non-exclusive right to co-promote DEXYCU (dexamethasone intraocular suspension) 9% for post-operative inflammation following ocular surgery in the U.S.
- Compensation: Eyepoint will pay the Company a fee based on quarterly sales of DEXYCU exceeding predefined volumes to specific customers.
- Governance: Co-promotion is supervised by a commercialization committee and a joint steering committee with equal representation from both parties.
- Duration: The agreement expires on August 1, 2025, subject to early termination.
Guidance, Risks, and Termination Provisions
The filing outlines specific termination rights and risks associated with the agreement:
- Termination for Cause: Either party may terminate for uncured material breach.
- Regulatory Risk: Either party may terminate if DEXYU loses "pass-through" payment status.
- Performance Risk: Eyepoint may terminate if the Company fails to achieve certain minimum sales levels during specified periods.
- Change of Control: The Company may terminate if Eyepoint undergoes a change of control.
- Convenience: The Company may terminate for convenience subject to an extended notice period.
Management commentary is limited to the summary of the agreement terms. The full text of the agreement is expected to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2020.
Investor Verification Checklist
- Verify the specific "predefined volumes" and fee calculation methodology in the full agreement text.
- Confirm the minimum sales levels required to prevent termination by Eyepoint.
- Monitor the regulatory status of DEXYCU's "pass-through" payment classification.
- Review the upcoming Form 10-Q for the complete agreement exhibit and any initial financial impact.